Clinical Drug Investigation

, Volume 22, Issue 10, pp 667–675 | Cite as

Impact of a Low-Dose Combination of Isradipine SRO and Spirapril on Left Ventricular Mass and Left Ventricular Performance in Patients with Hypertension and Left Ventricular Hypertrophy

  • David Pittrow
  • Gottfried Weidinger
  • Thomas Stoerk
  • Hermann Eichstaedt
Original Research Article



This study investigated the effects of a low-dose fixed combination of the ACE inhibitor isradipine SRO (slow-release oral) and the calcium antagonist spirapril on left ventricular hypertrophy (LVH) in patients with mild to moderate hypertension and LVH.


Open, non-randomised preliminary study.


20 patients (11 men and nine women, mean age 62 ± 12 years) with arterial hypertension and LVH were included in the study.


ECG-triggered nuclear magnetic resonance tomography (MRT), echocardiography and radionuclide ventriculography were used to measure parameters of left ventricular function at baseline and after 12 weeks’ treatment with a fixed combination of isradipine SRO 2.5mg and spirapril 3mg once daily.


Diastolic blood pressure was normalised (≤90mm Hg) after 6 weeks in 19 of 20 patients; only one patient required the dosage to be doubled to achieve BP control. Mean blood pressure was reduced from 163/99mm Hg at baseline to 150/84mm Hg at the end of the study (2p < 0.001). Mean end-systolic interventricular septum thickness measured by MRT was reduced from 20.1 to 18.2mm (2p < 0.001) after 12 weeks and end-systolic left ventricular posterior wall thickness from 19.2 to 17.7mm (2p < 0.001). Echocardiographic assessments resulted in similar findings. The left ventricular mass index calculated from echocardiographic data decreased from 195 to 164 g/m2 (2p < 0.001). A marked drop in total peripheral resistance from 1470 to 1233 units (2p < 0.001) was paralleled by a 14% decrease in systolic wall tension and an improvement in peak ventricular filling rate. Although there was a significant reduction in left ventricular mass, parameters of cardiac work did not change significantly, thus indicating a more efficient ventricular performance during treatment.


In this preliminary study, a low-dose combination of isradipine and spirapril induced a significant regression in LVH and an improvement in haemodynamic parameters in patients with mild to moderate hypertension and LVH. This finding needs to be confirmed in larger-scale, controlled studies.


Left Ventricular Hypertrophy Leave Ventricular Mass Index Moderate Hypertension Isradipine Peak Filling Rate 



This work was supported by a grant from Novartis Pharma, Nuremberg, Germany. We are indebted to HJ Kaiser, PhD, for his excellent work with the statistical planning and analysis.


  1. 1.
    Böhm M, Laragh JH, Zehender M, editors. From hypertension to heart failure. Berlin: Springer Verlag, 1998CrossRefGoogle Scholar
  2. 2.
    Levy D. Left ventricular hypertrophy: epidemiological insights from the Framingham Heart Study. Drugs 1988; 35Suppl. 5: 1–4PubMedCrossRefGoogle Scholar
  3. 3.
    McLenahan J, Henderson E, Morris K, et al. Ventricular arrhythmias in left ventricular hypertrophy. N Engl J Med 1987; 317: 787–92CrossRefGoogle Scholar
  4. 4.
    Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000; 342(24): 1778–85PubMedCrossRefGoogle Scholar
  5. 5.
    Fatkin D, Graham RM, Spirito P, et al. Prognostic value of left ventricular hypertrophy in hypertrophic cardiomyopathy. N Engl J Med 2001; 344: 63–5PubMedCrossRefGoogle Scholar
  6. 6.
    Hess OM, Ritter M, Schneider J, et al. Diastolic stiffness and myocardial structure in aortic valve replacement. Circulation 1984; 69: 855–65PubMedCrossRefGoogle Scholar
  7. 7.
    Schwartz F, Flameng W, Schaper J, et al. Correlation between myocardial structure and diastolic properties of the heart in chronic aortic valve disease: effect of corrective surgery. Am J Cardiol 1978; 42: 895–905CrossRefGoogle Scholar
  8. 8.
    Hort W. Microscopic pathology of heart muscle and of coronary arteries in arterial hypertension. In: Strauer BE, editor. The heart in hypertension. Berlin: Springer Verlag, 1981: 183–192CrossRefGoogle Scholar
  9. 9.
    Bevan RD, Eggena P, Hume WR, et al. Transient and persistent changes in rabbit blood vessels associated with maintained elevation in arterial pressure. Hypertension 1980; 2: 63–72PubMedCrossRefGoogle Scholar
  10. 10.
    Folkow B. Structure and function of the arteries in hypertension. Am Heart J 1987; 114: 938–48PubMedCrossRefGoogle Scholar
  11. 11.
    Sen S, Tarazi RC, Bumpus FM. Cardiac hypertrophy and antihypertensive therapy. Cardiovasc Res 1977; 11: 427–31PubMedCrossRefGoogle Scholar
  12. 12.
    Cruickshank JM, Lewis J, Moore V, et al. Reversibility of left ventricular hypertrophy by different types of antihypertensive therapy. J Hum Hypertens 1992; 6: 85–90PubMedGoogle Scholar
  13. 13.
    Eichstädt H, Danne O, Langer M, et al. Regression of left ventricular hypertrophy under ramipril treatment investigated by nuclear resonance imaging. J Cardiovasc Pharmacol 1989; 13Suppl. 3: 75–80CrossRefGoogle Scholar
  14. 14.
    Motz W, Strauer BE. Regression of structural cardiovascular changes by antihypertensive therapy. Hypertension 1984; 6Suppl. 3: 133–9Google Scholar
  15. 15.
    Eichstädt H, Schröder R, Richter W, et al. Untersuchungen zur Regression der linksventrikulären Hypertrophie — Messungen unter einer Kombinationstherapie von Co-Dergocrinmesilat und Nifedipin mittels Magnetresonanztomographie bei Patienten mit arterieller Hypertonie. Herz Kreisl 1991; 23Suppl. 12: 421–4Google Scholar
  16. 16.
    Fouad FM, Nakashima Y, Tarazi RC, et al. Reversal of left ventricular hypertrophy in hypertensive patients treated with methyldopa. Am J Cardiol 1982; 49: 795–801PubMedCrossRefGoogle Scholar
  17. 17.
    Frohlich ED, Apstern C, Chobanian AV, et al. The heart in hypertension. N Engl J Med 1992; 14: 998–1008CrossRefGoogle Scholar
  18. 18.
    Schmieder RE, Messerli F. Is the decrease in arterial blood pressure the sole factor for reduction of left ventricular hypertrophy? Am J Med 1992; 92Suppl 4B: 28–34CrossRefGoogle Scholar
  19. 19.
    Cutilletta AF, Dowell RT, Rudnik M, et al. Regression of myocardial hypertrophy. I. Experimental model, changes in heart weight, nucleic acids and collagen. J Mol Cell Cardiol 1975; 7: 767–81CrossRefGoogle Scholar
  20. 20.
    Motz W, Strauer BE. Left ventricular function and collagen content after regression of hypertensive hypertrophy. Hypertension 1989; 13: 43–50PubMedCrossRefGoogle Scholar
  21. 21.
    Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. JAMA 1996; 275: 1507–13PubMedCrossRefGoogle Scholar
  22. 22.
    Nakashima Y, Found FM, Tarazi RC. Regression of left ventricular hypertrophy from systemic hypertension by enalapril. Am J Cardiol 1984; 53: 1044–9PubMedCrossRefGoogle Scholar
  23. 23.
    Eichstädt HW, Felix R, Langer M, et al. Use of nuclear magnetic resonance imaging to show regression of hypertrophy with ramipril treatment. Am J Cardiol 1987; 59: 98D–103DPubMedCrossRefGoogle Scholar
  24. 24.
    Joint National Committee on Prevention, Detection, Evaluation, et al. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413–42CrossRefGoogle Scholar
  25. 25.
    Guidelines Subcommittee. 1999 WHO — International society of hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 154–83Google Scholar
  26. 26.
    Krönig B, Pittrow DB, Kirch W, et al. Different concepts in first-line treatment of mild-to-moderate essential hypertension: comparison of a low-dose reserpine-thiazide combination with nitrendipine monotherapy. Hypertension 1997; 29: 651–8PubMedCrossRefGoogle Scholar
  27. 27.
    Prisant LM, Weir MR, Papademetriou V, et al. Low-dose drug combination therapy: an alternative first-line approach to hyper-tension treatment. Am Heart J 1995; 130: 359–66PubMedCrossRefGoogle Scholar
  28. 28.
    Brunner HR, Menard J, Waeber B, et al. Treating the individual hypertensive patient: considerations on dose, sequential monotherapy and drug combinations. J Hypertens 1990; 8: 3–11PubMedCrossRefGoogle Scholar
  29. 29.
    MacConnachie AM, Maclean D. Low dose combination antihypertensive therapy: additional efficacy without additional adverse effects? Drug Saf 1995; 12: 85–90PubMedCrossRefGoogle Scholar
  30. 30.
    Kaplan NM. Combination therapy for hypertension. Am J Cardiol 1995; 76: 595–6PubMedCrossRefGoogle Scholar
  31. 31.
    Brogden RN, Sorkin EM. Isradipine: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension. Drugs 1995; 49(4): 618–49PubMedCrossRefGoogle Scholar
  32. 32.
    Diemont WL, Stegemann CJ, Beekman J, et al. Low-dose isradipine once daily effectively controls 24h blood pressure in essential hypertension. Am J Hypertens 1991; 4: 162–7Google Scholar
  33. 33.
    Noble S, Sorkin EM. Spirapril: a preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension. Drugs 1995; 19: 750–66CrossRefGoogle Scholar
  34. 34.
    Petersen LJ, Petersen JR, Talleruphuus U, et al. A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension. Clin Nephrol 2001; 55(5): 375–83PubMedGoogle Scholar
  35. 35.
    Kirkendall WM, Feinleib M, Freis ED, et al. AHA Committee Report: Recommendations for human blood pressure determination by sphygmomanometers. Hypertension 1981; 3: 510A–9APubMedGoogle Scholar
  36. 36.
    Devereux von RB, Reicheck N. Echocardiographic determination of left ventricular mass in man. Circulation 1977; 55: 613–8PubMedCrossRefGoogle Scholar
  37. 37.
    Messerli FH. Going to the heart of the matter. Circulation 1990; 81: 1128–35PubMedCrossRefGoogle Scholar
  38. 38.
    Mensah GA, Pappas TW, Koren MJ, et al. Comparison of classification of hypertension severity by blood pressure level and World Health Organisation criteria for prediction of concurrent cardiac abnormalities and subsequent complications in essential hypertension. J Hypertens 1993; 11: 1429–40PubMedCrossRefGoogle Scholar
  39. 39.
    Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561–6PubMedCrossRefGoogle Scholar
  40. 40.
    Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345–52PubMedGoogle Scholar
  41. 41.
    Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. JAMA 1996; 275: 1507–13PubMedCrossRefGoogle Scholar
  42. 42.
    Schunkert H, Hense HW, Holmer SR, et al. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N Engl J Med 1994; 330: 1634–8PubMedCrossRefGoogle Scholar
  43. 43.
    Schmieder R, Messerli FH, Garavaglia GE, et al. Does the renin-angiotensin-aldosterone system modify cardiac structure and function in essential hypertension? Am J Med 1988; 84 Suppl 3A: 136–9Google Scholar
  44. 44.
    Grodzicki T, Messerli FH, Soria F, et al. Determinants of left ventricular mass reduction in essential hypertension. J Hypertens Suppl. 1993 Dec;l 1Suppl 5: S364–5Google Scholar
  45. 45.
    Manolis AJ, Kolovou G, Handanis S, et al. Regression of left ventricular hypertrophy with isradipine in previously untreated hypertensive patients. Am J Hypertens 1993; 6: 86S–8SPubMedGoogle Scholar
  46. 46.
    Saragoca MA, Portela JE, Abreu P, et al. Reversal of left ventricular hypertrophy following treatment of hypertension with isradipine. J Cardiovasc Pharmacol 1991; 18Suppl. 3: S28–30PubMedGoogle Scholar
  47. 47.
    Bignotti M, Gaudio G, Gorini G, et al. Effects of sustained-release isradipine on left ventricular anatomy and function in systemic hypertension. Am J Cardiol 1993; 72: 1301–4PubMedCrossRefGoogle Scholar
  48. 48.
    Otterstad JE, Froeland G. Changes in left ventricular dimensions and haemodynamics during antihypertensive treatment with spiralpril for 36 months. Blood Press 1994; 2 Suppl: 69–72Google Scholar
  49. 49.
    Eichstädt H, Moersler J, Jochens R, et al. Regression of left ventricular hypertrophy under spirapril treatment investigated by nuclear resonance imaging. Perfusion 1996; 9: 338–43Google Scholar
  50. 50.
    Okin PM, Devereux RB, Jern S, et al. Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study. Am J Hypertens 2001; 14(8): 775–82PubMedCrossRefGoogle Scholar
  51. 51.
    Spilker B. Choosing and validating the clinical trial’s blind. In: Guide to clinical trials. New York: Raven Press, 1991Google Scholar
  52. 52.
    Eichstädt H, Felix R, Langer M, et al. Left ventricular hypertrophy regression under therapy with the ACE-inhibitor ramipril: a study with magnetic resonance imaging [Abstract]. Chest 1986; 89: 496SGoogle Scholar
  53. 53.
    Peschok RM. Magnetic resonance imaging of the heart: quantification. In: Marcus M, Schelbert H, Skorton D, Wolf G, editors. Cardiac imaging. Philadelphia: WB Saunders, 1991: 929Google Scholar
  54. 54.
    Devereux RB, Pini R, Aurigemma GP, et al. Measurement of left ventricular mass: methodology and expertise. J Hypertens 1997; 15(8): 801–9PubMedCrossRefGoogle Scholar
  55. 55.
    Missouris CG, Underwood R, Forbat SM, et al. Measurement of left ventricular mass in man. J Hypertens 1998; 16(2): 257–8PubMedCrossRefGoogle Scholar
  56. 56.
    Galderesi M, Celentano A, Garofalo M, et al. Reduction of left ventricular mass by short-term antihypertensive treatment with isradipine: a double-blind comparison with enalapril. Int J Clin Pharmacol Ther 1994; 32: 312–6Google Scholar
  57. 57.
    Motz W, Strauer BE. Rückbildung der hypertensiven Herzhypertrophic durch chronische Angiotensin-Konversions-enzymhemmung. Zeitschr Kardiol 1988; 77: 53–60Google Scholar
  58. 58.
    Strauer BE, Mahmoud MA, Bayer F, et al. Reversal of left ventricular hypertrophy and improvement of cardiac function in man by nifedipine. Eur Heart J 1984; 5 Suppl F: 53–60PubMedCrossRefGoogle Scholar
  59. 59.
    Muiesan G, Agabiti-Rosei E, Romanelli G, et al. Adrenergic activity and left ventricular function during treatment of essential hypertension with calcium antagonists. Am J Cardiol 1986; 57: 44–9CrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • David Pittrow
    • 1
  • Gottfried Weidinger
    • 2
  • Thomas Stoerk
    • 3
  • Hermann Eichstaedt
    • 4
  1. 1.Department of Clinical Pharmacology, Medical FacultyTechnical University of DresdenDresdenGermany
  2. 2.Department of Clinical ResearchNovartis Pharma GmbHNurembergGermany
  3. 3.Department of CardiologyKarl-Olga HospitalStuttgartGermany
  4. 4.Department of Cardiology, Virchow-Clinic of the CharitéHumboldt-University of BerlinBerlinGermany

Personalised recommendations